1.58

2.60% +0.04

Lexicon Pharmaceuticals Inc (LXRX)

Overview News Price History Option Chain Why LXRX Down? Discussions Forecast Stock Split

Lexicon Pharmaceuticals Inc stock is currently priced at $1.58, with a 24-hour trading volume of 1.25M. It has seen a +2.60% increased in the last 24 hours and a -20.20% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $1.55 pivot point. If it approaches the $1.62 resistance level, significant changes may occur.

Previous Close:

$1.54

Open:

$1.55

24h Volume:

1.25M

Market Cap:

$389.05M

Revenue:

$1.21M

Net Income/Loss:

$-177.12M

P/E Ratio:

-2.3235

EPS:

-0.68

Net Cash Flow:

$-162.37M

1W Performance:

-4.24%

1M Performance:

-20.20%

6M Performance:

+37.39%

1Y Performance:

-34.44%

1D Range:

$1.53

$1.61

52W Range:

$0.92

$3.789

Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile

Name

Lexicon Pharmaceuticals Inc

Sector

Healthcare (1191)

Industry

Biotechnology (688)

Phone

281-863-3000

Address

8800 Technology Forest Place, The Woodlands

Employee

174

Twitter

@LexPharma

Next Earnings Date

2024-05-10

Latest SEC Filings

LXRX's Discussions on Twitter

Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-07-23	Initiated	Jefferies	Hold
Aug-12-22	Initiated	Piper Sandler	Overweight
Jan-29-21	Upgrade	JP Morgan	Underweight → Neutral
Jan-29-21	Downgrade	Wedbush	Outperform → Neutral
Dec-08-20	Upgrade	Citigroup	Neutral → Buy
Nov-18-20	Upgrade	Gabelli & Co	Hold → Buy
Dec-11-19	Downgrade	Gabelli & Co	Buy → Hold
Nov-08-19	Downgrade	Citigroup	Buy → Neutral
Sep-11-19	Upgrade	Gabelli & Co	Hold → Buy
Jul-29-19	Downgrade	Stifel	Buy → Hold
Mar-25-19	Upgrade	Gabelli & Co	Sell → Hold
Jul-31-18	Reiterated	Stifel	Buy
Feb-23-18	Downgrade	Needham	Buy → Hold
Feb-14-18	Downgrade	JP Morgan	Neutral → Underweight
Mar-01-17	Reiterated	H.C. Wainwright	Buy
Mar-01-17	Reiterated	Wedbush	Outperform
Oct-07-16	Initiated	H.C. Wainwright	Buy
Aug-05-16	Reiterated	Wedbush	Outperform
Aug-02-16	Initiated	Citigroup	Buy
Mar-02-16	Reiterated	Wedbush	Outperform
Nov-09-15	Reiterated	Wedbush	Outperform
Sep-28-15	Upgrade	Gabelli & Co	Sell → Hold
Sep-18-15	Downgrade	Gabelli & Co	Hold → Sell
Aug-10-15	Downgrade	JP Morgan	Overweight → Neutral

View All

Lexicon Pharmaceuticals Inc Stock (LXRX) Latest News

Lexicon Pharmaceuticals to Host 2024 Investor Day

GlobeNewswire Inc.

All You Need to Know About Lexicon (LXRX) Rating Upgrade to Buy

Zacks Investment Research

Why LuxUrban Hotels Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Benzinga

Cintas Reports Upbeat Earnings, Joins PaySign, Noah Holdings And Other Big Stocks Moving Higher On Wednesday

Benzinga

Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo

GlobeNewswire Inc.

Lexicon (LXRX) Dips on Post Hoc Analysis Data on Sotagliflozin

Zacks Investment Research

Lexicon Pharmaceuticals Inc Stock (LXRX) Financials Data

Lexicon Pharmaceuticals Inc (LXRX) Revenue 2024

LXRX reported a revenue (TTM) of $1.21 million for the quarter ending December 31, 2023, a +766.91% rise year-over-year.

Lexicon Pharmaceuticals Inc (LXRX) Net Income 2024

LXRX net income (TTM) was -$177.12 million for the quarter ending December 31, 2023, a -73.74% decrease year-over-year.

Lexicon Pharmaceuticals Inc (LXRX) Cash Flow 2024

LXRX recorded a free cash flow (TTM) of -$162.37 million for the quarter ending December 31, 2023, a -80.05% decrease year-over-year.

Lexicon Pharmaceuticals Inc (LXRX) Earnings per Share 2024

LXRX earnings per share (TTM) was -$0.80 for the quarter ending December 31, 2023, a -31.15% decline year-over-year.

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that is in Phase 3 clinical trials for the treatment of type 1 and type 2 diabetes; LX2761, which is in Phase 1 clinical development for the treatment of diabetes; and LX9211 that is in Phase 1 clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Sanofi; Ipsen Pharma SAS; Bristol-Myers Squibb Company; and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.